Golotimod

Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) [1][2][3].

Product Specifications

CAS Number

[229305-39-9]

Product Name Alternative

SCV 07; Gamma-D-glutamyl-L-tryptophan

UNSPSC

12352209

Target

Bacterial; STAT

Type

Reference compound

Related Pathways

Anti-infection; JAK/STAT Signaling; Stem Cell/Wnt

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/golotimod.html

Purity

98.04

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 125 mg/mL (ultrasonic)

Smiles

O=C(CC[C@@](N)(C(O)=O)[H])N[C@]([H])(C(O)=O)CC1=CNC2=C1C=CC=C2

Molecular Formula

C16H19N3O5

Molecular Weight

333.34

References & Citations

[1]Rose WA 2nd, et al. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) . Int J Antimicrob Agents. 2008 Sep;32 (3) :262-6.|[2]Geiger JL, et al. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncol. 2016 May;56:84-92.|[3]Watkins B, et al. Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07) . Oral Dis. 2010 Oct;16 (7) :655-60.